A JAK2 V617F
Abstract:
A JAK2 V617F mutation is frequently found in several BCR/ABL-negative myeloproliferative disorders. To address the contribution of this mutant to the pathogenesis of these different myeloproliferative disorders, we used an adoptive transfer of marrow cells transduced with a retrovirus expressing JAK2 V617F in recipient irradiated mice. Hosts were analyzed during 6 months after transplantation. For a period of 3 months, mice developed polycythemia, macrocytosis and usually peripheral blood granulocytosis. Transient thrombocytosis was only observed in a low expresser group.
All mice displayed trilineage hyperplasia in marrow and spleen along with an amplification of myeloid and erythroid progenitor cells and a formation of endogenous erythroid colonies. After 3-4 months, polycythemia regressed, abnormally shaped red blood cells and platelets were seen in circulation and a deposition of reticulin fibers and collagen was observed in marrow and spleen. Development of fibrosis was associated with anemia, thrombocytopenia, high neutrophilia and massive splenomegaly. These features mimic human Polycythemia Vera and its evolution towards myelofibrosis. This work demonstrates that JAK2 V617F is sufficient for polycythemia and fibrosis development and offers an in vivo model to assess novel therapeutic approaches for 
Introduction
Myeloproliferative disorders (MPDs) include four main entities: essential thrombocythemia (ET), polycythemia Vera (PV), idiopathic myelofibrosis (IMF) and chronic myeloid leukemia (CML). MPDs also include some rare and poorly characterized disorders with common clinical and biologic features found in MPDs. 1 These diseases are characterized by overproduction of blood cells without obvious blockage in maturation.
In CML, hyperplasia of the granulocytic lineage predominates while in PV or ET and IMF, the erythroid or granulocytic and megakaryocytic lineages are prevalent, respectively. MPDs share the common features of being clonal hematopoietic disorders originating from the transformation of a multipotent progenitor cell and to exhibit progenitor cell hypersensitive to growth factors. 1 In PV, Endogenous Erythroid Colony (EEC) formation 2 is commonly used in clinical practice for diagnosis. In addition, hyper responsiveness to factors such as such as erythropoietin (Epo), interleukin 3 (IL-3),
Insulin growth factor I (IGF-1), Stem cell factor (SCF) and Granulo-macrophage colony stimulating factor (GM-CSF) has also been demonstrated. 2, 3 Similarly, megakaryocytic progenitor cells from ET and IMF are hypersensitive to thrombopoietin (TPO). 4 We 5 , and others [6] [7] [8] , have recently identified in BCR/ABL-negative MPDs a unique and recurrent acquired mutation of the JAK2 protein leading to a valine-to-phenylalanine substitution (JAK2 V617F ) in the auto-inhibitory JH2 (JAK Homology) domain. The JAK2 V617F mutation is found in a majority of PV patients and in around half of the patients suffering from IMF or ET. 6, 9 Furthermore, this mutation has been also identified in rare patients suffering from acute myeloid leukemia, other MPDs and myelodysplastic syndromes. 9 Although PV, ET and IMF exhibit significant phenotypic mimicry and a general pattern of clinical evolution, it still remains puzzling how a unique mutation can be involved in such a diversity of diseases. In order to unravel this question and determine the consequences of this mutation on normal hematopoiesis, we studied the in 
Construction and production of retroviruses

Murine JAK2
V617F and wild type JAK2 (JAK2 WT ) pMEGIX retroviral vector were previously described. 5 VSV-G pseudotyped viral particles were produced into the 293 EBNA cells 10 . Ecotropic virus producing cell lines were then generated from two successive infections of the GP+E-86 packaging cell line (kindly supplied by Dr A. Bank, Columbia University, New York, NY) 11 with concentrated virus supernatants. High virus producer clones were selected for their ability to infect a high percentage of EpoR-FDC-P1 cells by measuring GFP expression. Two independent clones were used to generate two different sets of primary recipient mice.
BM transduction procedure
All procedures were approved by the Institut Gustave Roussy ethic committee. C57BL/6J female mice (2-4 months-old) were purchased from Janvier (Le Genest, France 
Analysis of mice
Hemoglobin (Hb), mean corpuscular volume (MCV), hematocrit, red blood (RBC), platelet and white blood (WBC) counts, and the lymphocyte/granulocyte ratio were determined using an automated counter (MS9, Schloessing Melet, Cergy-Pontoise, France) on blood collected from the retro-orbital plexus in citrated tubes. BM cells were removed by flushing both femurs. Spleens were weighed and single cell suspensions were prepared. Differential cell counts were performed after May-Grünwald-Giemsa staining of blood smears or spleen and BM cell cytospins.
For histopathology analysis, femur and spleen were fixed in formaldehyde, decalcified and paraffin embedded. Sections (4.5 µm) were stained with hematoxylin/eosin, periodic acid Schiff and Giemsa for cytology analysis. Reticulin fibers were revealed by silver staining according to Gordon Sweet method, and collagen was revealed by trichrome staining. 
Progenitor cell study
Progenitor cell assays were carried out in 1ml methylcellulose "MethoCult 32/34" (Stemcell Technologies) without stimulus or maximally stimulated by IL3, IL6, TPO, SCF, and EPO. Cultures were scored in duplicate or quadruplicate after different days of incubation: 2 days for CFU-E assays and 7 days for burst forming unit-erythroid (BFU-E) and CFU-GM assays. Total progenitor cell number was calculated assuming that one femur represented 6% of the total marrow and from the number of cells isolated from the spleen.
Cell signalling stimulation and Western blot analysis
Spleen cells were dissociated from freshly excised spleen and rinsed three times with PBS. Then, spleen cells were cultivated in DMEM supplemented with 1% FBS for 16 
Southern Blot
High molecular weight DNAs were prepared from BM and spleen, digested with BamH1 or EcoRI restriction endonuclease and subjected to southern blot analysis as previously described. 14 Blots were hybridized with a GFP probe isolated from the pMEGIX-JAK2 vector
Statistical analysis
Results are presented as mean ± SEM and data were analyzed with the 2-tailed Student t test.
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Results
In vitro and ex-vivo retroviral JAK2
V617F gene activity.
To study the in vivo effect of the JAK2 V617F mutation, recipient mice were transplanted with BM cells transduced with a retrovirus expressing murine JAK2 These results show that the murine JAK2 V617F virus leads to constitutive activation of JAK2 downstream effectors in primary cells.
Retroviral gene expression and integration in the different sets of mice.
We studied 65 JAK2 V617F virus transduced mice derived from 3 groups of primary recipients (MP0, n=4, MP1, n=14, MP2, n=15) generated from 3 independent transduction and 2 groups of secondary recipients derived from the transplantation of marrow cells collected from a mouse belonging to the MP0 (MS1 n=15) or the MP1 group (MS2, n=17). In parallel, we generated control primary or secondary recipients reconstituted with BM cells transduced with the JAK2 WT or empty retroviruses. Mice from the MP0 group are included in this work only for histological analysis. All engrafted mice expressed GFP in 50 to >90% of blood cells. GFP expression levels clearly differed from one group to the other but were similar in mice from the same group (data not shown). Retroviral JAK2 mRNA levels were assessed by QTPCR in marrow and spleen. The lowest levels were found in the MS1 group and the highest levels were found in the MP2 group. Intermediate levels were seen in the MP1 and MS2 groups, the For personal use only. on November 12, 2017. by guest www.bloodjournal.org From latest being derived from one mouse belonging to the MP1 group (data not shown). The same trend of expression was observed when total (endogenous and retroviral) JAK2 mRNA levels were measured in spleens, using a second QTPCR approach, suggesting that most JAK2 mRNA was from retroviral origin. Indeed, the total JAK2/endogenous JAK2 ratios, using as endogenous JAK2 the level determined in empty virus recipient mice, were 15±6, 36±1, 2.6±0. 5 Histological examination of the spleens revealed striking differences between mice studied early (≤ 3 months, 98 days) or late (> 4 months, 131 days) after transplantation ( Figure 5.C-D) . In the early stages, hyperplasia of the red pulp was the dominant feature.
Malpighian corpuscles were present in the white pulp. However they were reduced in size, had no clear germinal center, and were blended by invasion of non-lymphoid cells.
Hyperplasia of the red pulp was dominated by normally differentiated erythroid cells.
Clustered megakaryocytes with multilobulated nucleus and emperipolesis were observed.
Granulocytes were in unusual high numbers near the capsule and around the trabeculae.
In later stages, trilineage hyperplasia with a prevalence of erythroid cells was still present in the red pulp. The white pulp was either completely blended or partially preserved. Mice were divided into three groups displaying no fibrosis (n=5) (early stages), lowgrade fibrosis (n=3) or high-grade fibrosis (n=4) (late stages). Interestingly, there was a clear trend associating development of fibrosis with anemia (3 of 4 mice being anemic in the high-grade group), thrombocytopenia, high neutrophilia (all high-grade fibrosis mice having the highest WBC count) and massive splenomegaly ( Figure 6 ). Circulating blood progenitor cells were detected in late stages in unusual high numbers in JAK2 V617F mice compared to control JAK2 WT mice (Figure 7 .B).
In the absence of added growth factor, marrow and spleen-derived CFU-E colonies were always detected in JAK2 V617F virus recipient mice, as well as CFU-GM-derived colonies but in a low percentage compared to endogenous CFU-E (Figure 7 .C). Rare endogenous BFU-E were observed. progenitors, was amplified mainly due to splenic hematopoiesis. This MPD perfectly mimicks human PV including its evolution towards the "spent" phase.
This work demonstrates the cause-effect of the JAK2 V617F mutation in the development of human PV. The main erythroid phenotype of these mice can be related to the primordial importance of JAK2 signaling in erythropoiesis. Indeed, the lethal mi-gestational phenotype of the JAK2 KO mice has been attributed to a block in definitive erythropoiesis. 15, 16 Furthermore, the receptor for Epo (EpoR) strictly requires JAK2 for both signaling and trafficking to the cell surface, 17 contrasting with other hematopoietic growth factor receptors that utilize JAK2 but also other JAK family members (JAK1 and Tyk2) either for signaling or for cell surface expression. 18, 19 Besides this prevalent activity on erythroid cells, JAK2 V617F also favors, to a lesser extend, the granulocytic and megakaryocytic lineages as evidenced by hyperplasia of these cells in organs leading to granulocytosis and possible thrombocytosis. This is in sharp contrast with the myeloid and lymphoid proliferation disease induced by the TEL/JAK2 fusion protein, a disease that is not associated with a polycythemia. 20 This result suggests that JAK2 V617F activity is dependent at some extend upon binding to receptors, especially those controlling the For personal use only. on November 12, 2017. by guest www.bloodjournal.org From erythroid, the granulocytic and megakaryocytic lineages (EpoR, Mpl and G-CSF) as recently suggested. 21 A surprising finding was the regression of erythrocytosis, with possible occurrence of anemia despite a sustained JAK2 V617F expression. This is in contrast with our Epo overproduction model of polycythemia in which erythrocytosis was maintained for up to one year. 22 Therefore, decline of polycythemia cannot be attributed to the incapacity of the mice to sustain high polycythemia for a prolonged period. Regression of erythropoiesis was associated with myelofibrosis. Similarly, myelofibrosis is observed in PV patients only a few years, sometime 20 years, after diagnosis. This so-called "spent"
phase, best characterized by polycythemia decline, spleen enlargement, thrombocytopenia with high leukocytosis and circulating precursor cells, shares these features in common with our animal model. Occurrence of various grades of fibrosis in all mice studied late after transplantation without evidence of clonal hematopoiesis strongly suggests that myelofibrosis is the direct consequence of long-term sustained JAK2 V617F kinase activity rather than additional molecular events.
Myelofibrosis is a common feature of MPD, notably of IMF but also of PV, ET and CML. 23 Animal models for IMF have been previously developed using in vivo overexpression of TPO (TPO   high   ) 12 or transgenic mice expressing low level of the transcription factor GATA-1 (GATA-1 low mice). 24 We have shown in the TPO high model that TGF-β1 had a prominent role in fibrosis induction. 25 It is therefore tempting to speculate that the release of TGF-β1 by megakaryocytes in JAK2 V617F mice may be responsible for myelofibrosis. TGF-β1 is probably released by megakaryocytes as a result of dysfunctional megakaryocytes or pathological interactions with neutrophils.
Dysmegakaryopoiesis and emperipolesis were observed in our model suggesting that both mechanisms might be involved.
The JAK2 V617F mutation is primarily identified in most PV patients but also in half of IMF and ET patients and with a low frequency in other diseases. Our study shows that For personal use only. on November 12, 2017. by guest www.bloodjournal.org From For personal use only. on November 12, 2017. by guest www.bloodjournal.org From
